09.18.23
Astrea Bioseparations, a provider of bio separation and purification technologies expanded its manufacturing and warehousing capabilities in the U.S. The increased capacity reflects growing demand for the company’s chromatography solutions in North American markets.
In a statement, the company said that the new, 12,000 sq. ft. facility will allow Astrea Bio to bring its products to customers within lead times of 3-5 weeks for off-the-shelf products, and 6-8 weeks for large-scale resin orders. The site expands the company’s U.S. footprint by over fourfold, supporting its continued growth trajectory as it also increases its workforce by up to 9 percent over an 18-month period.
Scheduled to be completed in 4Q23, the facility, located in Canton, MA, will provide significantly increased manufacturing and warehousing capacity. Hosting a variety of workspaces, including cleanroom laboratories for column packing services, offices, warehousing, and column assembly spaces, the facility will provide a vital hub to Astrea Bio’s North American supply network, as well as locally available technical expertise and customer support.
In addition, dedicated column packing cleanrooms will increase production capacity for pre-packed column products and services. Increased warehousing space will be available for all products, including the company’s range of affinity, hydrophobic interaction chromatography and ion exchange adsorbents and resins for commercial-scale biologic production, and its AstreAdept range of nanofiber-based purification technology for efficient production of cell and gene therapies.
“Expanding our presence in the US reflects growing demand for our chromatography products and services to support effective development and production of cutting-edge biologics, including cell and gene therapies,” said Chris Brown, operations Director at Astrea Bioseparations. “The new site gives us greater capacity to support new and existing customers by providing innovative and high-quality products, within market-leading timeframes, as well as offering local technical expertise.”
In a statement, the company said that the new, 12,000 sq. ft. facility will allow Astrea Bio to bring its products to customers within lead times of 3-5 weeks for off-the-shelf products, and 6-8 weeks for large-scale resin orders. The site expands the company’s U.S. footprint by over fourfold, supporting its continued growth trajectory as it also increases its workforce by up to 9 percent over an 18-month period.
Scheduled to be completed in 4Q23, the facility, located in Canton, MA, will provide significantly increased manufacturing and warehousing capacity. Hosting a variety of workspaces, including cleanroom laboratories for column packing services, offices, warehousing, and column assembly spaces, the facility will provide a vital hub to Astrea Bio’s North American supply network, as well as locally available technical expertise and customer support.
In addition, dedicated column packing cleanrooms will increase production capacity for pre-packed column products and services. Increased warehousing space will be available for all products, including the company’s range of affinity, hydrophobic interaction chromatography and ion exchange adsorbents and resins for commercial-scale biologic production, and its AstreAdept range of nanofiber-based purification technology for efficient production of cell and gene therapies.
“Expanding our presence in the US reflects growing demand for our chromatography products and services to support effective development and production of cutting-edge biologics, including cell and gene therapies,” said Chris Brown, operations Director at Astrea Bioseparations. “The new site gives us greater capacity to support new and existing customers by providing innovative and high-quality products, within market-leading timeframes, as well as offering local technical expertise.”
